Emergent Biosolutions
EBS
232 hedge funds and large institutions have $1.28B invested in Emergent Biosolutions in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 64 increasing their positions, 102 reducing their positions, and 38 closing their positions.
252% more call options, than puts
Call options by funds: $5.37M | Put options by funds: $1.52M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.62% less ownership
Funds ownership: 82.77% → 81.15% (-1.6%)
9% less funds holding
Funds holding: 255 → 232 (-23)
26% less capital invested
Capital invested by funds: $1.72B → $1.28B (-$438M)
37% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 102
45% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 38
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$23.3M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$19.9M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$19.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$15.3M |
| 5 |
Morgan Stanley
New York
|
+$8.96M |
Top Sellers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$24.6M |
| 2 |
Two Sigma Investments
New York
|
-$10.6M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$9.43M |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$9.37M |
| 5 |
Renaissance Technologies
New York
|
-$8.98M |
EBS Hedge Fund Activity: Q2 2022 in Review
232 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2022, worth a combined $1.28B — down 26% from $1.72B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of EBS and 21 opened new positions — a net loss of 17 holders — while 102 trimmed existing stakes and 64 added.
The largest buyer was State Street, adding an estimated $23.3M. The largest seller was Janus Henderson Group, cutting an estimated $24.6M.
- 232 institutional investors held Emergent Biosolutions (EBS) as of Q2 2022, down from 255 in Q1 2022.
- Funds reported $1.28B of Emergent Biosolutions stock for Q2 2022, down 26% quarter-over-quarter.
- 21 funds opened new Emergent Biosolutions positions in Q2 2022 and 38 closed out, a net change of -17 holders.
- The largest Emergent Biosolutions buyer in Q2 2022 was State Street, an estimated $23.3M added.
- The largest Emergent Biosolutions seller in Q2 2022 was Janus Henderson Group, an estimated $24.6M sold.
Based on aggregated 13F filings for Q2 2022.